

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)



(10) International Publication Number
WO 2021/199006 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) A61K 39/00 (2006.01)
- (21) **International Application Number:**
PCT/IB2021/052793
- (22) **International Filing Date:**
03 April 2021 (03.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
202041014994 04 April 2020 (04.04.2020) IN
CU-2020-0027 17 April 2020 (17.04.2020) CU

(71) **Applicants:** BIOCON LIMITED [IN/IN]; 20th KM, Hosur Road, Electronic City, Karnataka, Bangalore 560100 (IN). CENTRO DE INMUNOLOGÍA MOLECULAR [CU/CU]; Calle 216, Esquina 15, Atabey, Playa, La Habana (CU).

(72) **Inventors:** NAIR, Pradip; 303, Aikya Apartments off Bannerghatta Road, Karnataka, Bangalore 560076 (IN). CASIMIRO, Jose Enrique Montero; 5166 Whitman Way, Apt 205., Carlsbad, California 92008 (US). MAZUMDAR SHAW, Kiran; # 58, Glenmore, Goolimangala, Huskur Village Road, Karnataka, Bangalore 560099 (IN). BUGHANI, Usha; D3-507 SNN Raj Serenity Begur Koppa main Road, Yelenahalli, Karnataka, Bangalore 560068 (IN). ATHALYE, Sandeep Nilkanth; E-1902, Salarpuria Seniorita, Sarjapur Road, Opp. Wipro Gate, Karnataka, Bangalore 560035 (IN). RAMAKRISHNAN, Melarkode Subbaraman; 288 4th Main 8th Cross Rainbow, Drive Layout, Sarjapur Road, Karnataka, Bangalore 560035 (IN). CROMBET RAMOS, Tania; Calle B No. 8302 entre 5a y 100, Altahabana, Boyeros, La Habana 10800 (CU). LEÓN MONZÓN, Kalet; Calle 31 e/ 320 y 322 # 32009, Fraga, La Lisa, La Habana 17100 (CU). RAMOS SUZARTE, Mayra; Calle 184 edif BEE1 apto 12 e/ 1ra y 5ta, Flores, Playa, La Habana 11600 (CU).

(74) **Agent:** MAJUMDAR, Subhatosh et al.; S. Majumdar & Co., 5, Harish Mukherjee Road, West Bengal, Kolkata 700 025 (IN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) **Title:** ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING AND REDUCING NEGATIVE EFFECTS OF A CORONAVIRUS INCLUDING COVID-19

(57) **Abstract:** The present invention provides the use of anti-CD6 antibodies that specifically bind to domain 1 of CD6 for treating effects of a coronavirus or bacterial agent and particularly COVID-19 and variants thereof. The anti-CD6 antibodies of the present invention exhibit therapeutic activity by reducing the overactive immune response, such as the high expression levels of cytokines.



WO 2021/199006 A1